Pediatric Oncology Trials Should Start After Adult Phase I Data – Subcmte.
Executive Summary
Pediatric oncology trials usually should be initiated after collection of data from Phase I adult trials, FDA's Pediatric Subcommittee of the Oncologic Drugs Advisory Committee recommended Oct. 17
You may also be interested in...
Cancer Drug Accelerated Approval Could Be Based On Pediatric Studies
Pharmaceutical companies could gain accelerated approval for oncologic agents based solely on pediatric testing of those drugs, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, suggested
Cancer Drug Accelerated Approval Could Be Based On Pediatric Studies
Pharmaceutical companies could gain accelerated approval for oncologic agents based solely on pediatric testing of those drugs, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, suggested
FDA Pediatric Rule “Usurps” Pediatric Exclusivity Law, Court Rules
The "command and control" approach of FDA's pediatric rule is "incompatible" with the Best Pharmaceuticals for Children Act, a Washington, D.C. federal judge ruled in striking down the agency reg